StreptAnova® Phase 1 clinical trial to start: Vaccine designed to prevent Streptococcus pyogenes infections
by Staff from Outbreak News Today on (#JEZY)
The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR) located at the University of Saskatchewan, and Vaxent in Memphis, Tennessee, are pleased to announce the initiation of a Phase 1 clinical trial of StreptAnova(R), a vaccine designed to prevent Group A streptococcal (GAS) infections. The trial will be ["]
